Sign inJoin waitlistJoin the waitlist

Michelle Loch

Associate Professor of Clinical Medicine · Louisiana State University School of Medicine

Credentials: · · · · · ·

History

Louisiana State University School of Medicine
Present
Louisiana State University School of Medicine
Present

Hematology and Medical Oncology
Boston University Medical Center
2008–2011
Internal Medicine
University of Virginia Medical Center
2005–2008
St. George’s University School of Medicine
2001–2005

Research

Overview of breast cancer collaborative stage data items--their definitions, quality, usage, and clinical implications: a review of SEER data for 2004-2010
Cancer · 2014 · 61 citations
Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+/PR+, HER2- vs. triple-negative
Breast Cancer Research and Treatment · 2018 · 43 citations
Comparison between endoscopic ultrasound and magnetic resonance imaging for the staging of pancreatic cancer
Pancreas · 2011 · 21 citations

KT
Katharine Thomas
3 papers · 3 as a fellow
Amber Karamanis
2 papers · 1 as a resident
AM
Anshu Mahajan
2 papers · 2 as a fellow
ED
Erin Dauchy
2 papers · 2 as a fellow
MK
Michael Kahaleh
2 papers
Vanessa Shami
2 papers
Adam Riker
1 paper
AG
Agustin Garcia
1 paper
AS
Alejandro Stella
1 paper · 1 as a resident
Amelia Jernigan
1 paper
Anahid Pahlawanian
1 paper · 1 as a fellow
Andrew Brock
1 paper

Clinical trials

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2037
E-Mindfulness Approaches for Living After Breast Cancer
Site PI · Recruiting · Phase 3
NRG Oncology
2025–2030
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Site PI · Recruiting · Phase 3
Stemline Therapeutics, Inc.
2024–2032
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2023–2032